Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions.
Aged
Biomarkers, Tumor
/ analysis
Databases, Factual
Diagnosis, Differential
Female
Humans
Immunohistochemistry
Male
Middle Aged
Mucins
/ analysis
Neoplasm Grading
Neoplasms, Cystic, Mucinous, and Serous
/ chemistry
Pancreatic Cyst
/ chemistry
Pancreatic Intraductal Neoplasms
/ chemistry
Pancreatic Neoplasms
/ chemistry
Predictive Value of Tests
Retrospective Studies
Up-Regulation
Journal
HPB : the official journal of the International Hepato Pancreato Biliary Association
ISSN: 1477-2574
Titre abrégé: HPB (Oxford)
Pays: England
ID NLM: 100900921
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
16
01
2018
revised:
25
04
2018
accepted:
09
07
2018
pubmed:
18
8
2018
medline:
14
4
2020
entrez:
18
8
2018
Statut:
ppublish
Résumé
Intraductal papillary mucinous neoplasms (IPMN) are currently managed based on imaging characteristics and cyst fluid sampling. This study was designed to determine if MUC13, a glycoprotein aberrantly overexpressed in pancreatic adenocarcinoma, might aid in distinguishing high-risk lesions (high grade dysplasia/invasive disease) from low-grade lesions. MUC13 immunohistochemical staining was performed on surgically resected formalin-fixed tissue specimens from 49 IPMNs and 23 non-mucinous cysts. Membranous MUC13 expression was measured by H-score, which quantifies staining intensity and the percentage of cells involved (range 0-300). MUC13 expression was detected in all IPMNs and was significantly greater than in non-mucinous cysts (median 210 vs 40, p < 0.001). MUC13 expression was similar among main (n = 26), branch (n = 15), and mixed (n = 8) duct lesions (median 210, 200, 225, respectively). The highest expression was observed in tumors with intestinal and pancreatobiliary histologic features (both median 225) and the lowest in gastric type lesions (median 200). MUC13 expression was significantly greater in high-risk lesions (n = 21) compared to those with low-grade dysplasia (n = 28) (median 250 vs 195, p < 0.001). MUC13 expression was significantly greater in high-risk IPMNs in this analysis. The preoperative assessment of MUC13 in cyst fluid samples warrants further investigation.
Sections du résumé
BACKGROUND
Intraductal papillary mucinous neoplasms (IPMN) are currently managed based on imaging characteristics and cyst fluid sampling. This study was designed to determine if MUC13, a glycoprotein aberrantly overexpressed in pancreatic adenocarcinoma, might aid in distinguishing high-risk lesions (high grade dysplasia/invasive disease) from low-grade lesions.
METHODS
MUC13 immunohistochemical staining was performed on surgically resected formalin-fixed tissue specimens from 49 IPMNs and 23 non-mucinous cysts. Membranous MUC13 expression was measured by H-score, which quantifies staining intensity and the percentage of cells involved (range 0-300).
RESULTS
MUC13 expression was detected in all IPMNs and was significantly greater than in non-mucinous cysts (median 210 vs 40, p < 0.001). MUC13 expression was similar among main (n = 26), branch (n = 15), and mixed (n = 8) duct lesions (median 210, 200, 225, respectively). The highest expression was observed in tumors with intestinal and pancreatobiliary histologic features (both median 225) and the lowest in gastric type lesions (median 200). MUC13 expression was significantly greater in high-risk lesions (n = 21) compared to those with low-grade dysplasia (n = 28) (median 250 vs 195, p < 0.001).
CONCLUSION
MUC13 expression was significantly greater in high-risk IPMNs in this analysis. The preoperative assessment of MUC13 in cyst fluid samples warrants further investigation.
Identifiants
pubmed: 30115565
pii: S1365-182X(18)32694-7
doi: 10.1016/j.hpb.2018.07.009
pmc: PMC6349495
mid: NIHMS1503626
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MUC13 protein, human
0
Mucins
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-95Subventions
Organisme : NCI NIH HHS
ID : R01 CA142736
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Informations de copyright
Copyright © 2018 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.
Références
Nat Rev Cancer. 2009 Dec;9(12):874-85
pubmed: 19935676
Mol Cancer Ther. 2012 Jan;11(1):24-33
pubmed: 22027689
Clin Cancer Res. 2011 Mar 15;17(6):1502-8
pubmed: 21266527
J Am Coll Surg. 2017 May 18;:
pubmed: 28633941
Ann Surg. 2010 May;251(5):937-45
pubmed: 20395854
Ann Surg Oncol. 2008 Nov;15(11):3187-92
pubmed: 18766406
Scand J Gastroenterol. 2013 Oct;48(10):1183-7
pubmed: 24047396
J Pathol. 2002 Jun;197(2):201-10
pubmed: 12015744
Oncotarget. 2014 Sep 15;5(17):7599-609
pubmed: 25277192
Am J Gastroenterol. 2015 Jun;110(6):909-14
pubmed: 25986360
Pancreas. 2011 Oct;40(7):1024-8
pubmed: 21775920
J Am Coll Surg. 2015 Feb;220(2):243-53
pubmed: 25592469
Mol Cell Proteomics. 2013 Oct;12(10):2724-34
pubmed: 23836919
Curr Surg. 2000 Nov;57(6):610-614
pubmed: 11120307
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Surg Clin North Am. 2016 Dec;96(6):1431-1445
pubmed: 27865286
Surgery. 2012 Sep;152(3 Suppl 1):S4-12
pubmed: 22770958
Cancer Res. 1986 Aug;46(8 Suppl):4244s-4248s
pubmed: 3524805
Clin Cancer Res. 2017 Aug 15;23(16):4865-4874
pubmed: 28424202
Ann Surg. 2006 Oct;244(4):572-82
pubmed: 16998366
HPB (Oxford). 2018 Jun;20(6):563-572
pubmed: 29352660
Hum Pathol. 2018 Feb;72:144-152
pubmed: 29180250
Br J Surg. 2010 Aug;97(8):1269-78
pubmed: 20602499
Gastroenterology. 2004 May;126(5):1330-6
pubmed: 15131794
Am J Gastroenterol. 2001 May;96(5):1429-34
pubmed: 11374678
Pathol Int. 1998 Apr;48(4):319-22
pubmed: 9648163
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
Oncogene. 2017 Jan 26;36(4):491-500
pubmed: 27321183
Pancreatology. 2006;6(1-2):17-32
pubmed: 16327281
PLoS One. 2016 Dec 19;11(12):e0167070
pubmed: 27992432
Am J Surg Pathol. 2001 Jul;25(7):942-8
pubmed: 11420467
J Am Coll Surg. 2017 Apr;224(4):461-469
pubmed: 28088598
Ann Surg Oncol. 2011 Jan;18(1):199-206
pubmed: 20717734
J Gastrointest Surg. 2013 Jan;17(1):78-84; discussion p.84-5
pubmed: 22948841
Cancer. 2002 Jan 1;94(1):62-77
pubmed: 11815961
Ann Surg. 2006 May;243(5):673-80; discussion 680-3
pubmed: 16633003